Han Lab | Yong Han, Ph.D.
Our laboratory develops novel living biotherapeutics using synthetic biology, with an emphasis on engineering probiotics to selectively colonize disease sites, sense disease-associated biomarkers, and release therapeutic molecules on demand.
By designing and constructing synthetic gene circuits, we engineer probiotic bacteria to recognize disease-associated signals and respond to them specifically. Our research focuses on achieving selective colonization of engineered probiotics at disease sites, using synthetic gene circuits to sense disease-associated biomarkers, and achieving spatiotemporal control over the expression and release of payloads. These studies aim to develop living biotherapeutic systems capable of autonomously responding to disease microenvironments, providing new therapeutic strategies for cancer, infectious diseases, immune disorders, and metabolic diseases.
We are also interested in exploring the untapped biosynthetic potential of the human microbiome and other underexplored microbial sources. Through genome mining, biosynthetic gene cluster identification, heterologous expression, and metabolic pathway engineering, we aim to discover novel bioactive molecules and investigate their biosynthetic pathways and potential therapeutic applications.
/prod01/fit-cdn-pxl/media/fit-website/site-assets/images/FT-Horiz_crimson-gold.png)